Johnson & Johnson (NYSE:JNJ) Shares Acquired by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,842 shares of the company's stock after buying an additional 4,301 shares during the quarter. Frank Rimerman Advisors LLC's holdings in Johnson & Johnson were worth $5,809,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Innealta Capital LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth about $27,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after purchasing an additional 91 shares during the period. MFA Wealth Advisors LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at approximately $43,000. Fairfield Financial Advisors LTD purchased a new position in Johnson & Johnson in the 2nd quarter valued at approximately $46,000. Finally, Fairway Wealth LLC raised its holdings in shares of Johnson & Johnson by 217.1% in the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company's stock valued at $49,000 after purchasing an additional 228 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.72 during midday trading on Monday, hitting $161.60. The stock had a trading volume of 4,802,681 shares, compared to its average volume of 6,999,143. The company has a market capitalization of $388.92 billion, a PE ratio of 10.08, a P/E/G ratio of 2.90 and a beta of 0.52. The stock has a 50 day moving average price of $163.41 and a two-hundred day moving average price of $155.10. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.46%. The firm's revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.66 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is currently 30.92%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. TD Cowen reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a "buy" rating on the stock in a report on Thursday, July 18th. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $175.93.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.